Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
ACLASTA (zoledronic acid 5mg/100mL) solution for intravenous infusion - Association with renal dysfunction - For the Public
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 41 K)Contact: Marketed Health Products Directorate
The Health Products and Food Branch (HPFB) posts on the Health Canada Web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
PUBLIC COMMUNICATION
Health Canada Endorsed Important Safety Information on
ACLASTA (zoledronic acid)
October 14, 2010
Subject: Association of ACLASTA* (zoledronic acid 5 mg/100 mL) solution for intravenous infusion with kidney dysfunction.
Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada, would like to remind patients of important safety information on kidney dysfunction based on post-marketing experience with ACLASTA*.
The Canadian prescribing information for ACLASTA* is being revised to further emphasize the following safety information:
- ACLASTA* has been associated with kidney dysfunction manifested as worsening of kidney function, and in rare cases, acute kidney failure.
- Kidney impairment has been observed following the administration of ACLASTA*, occasionally after a single administration.
- Kidney failure requiring dialysis or with a fatal outcome has occurred especially in patients with history of kidney impairment or other risk factors. Risk factors include advanced age, some concomitant medicinal products (e.g. any medicines known to be harmful to the kidneys) or dehydration occurring after ACLASTA* administration.
As per the current prescribing and consumer information for ACLASTA*, please note the following important considerations to minimize the risk of renal adverse events:
- Before you take ACLASTA* talk to your doctor or pharmacist if you have, or used to have, a kidney problem.
- Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including any you have bought without a prescription. It is especially important for your doctor to know if you are taking any medicines known to be potentially harmful to the kidneys (such as nonsteroidal anti-inflammatory drugs (NSAIDs)).
- Make sure that you drink a sufficient amount of water (at least two glasses or 500 mL) before and after your treatment with ACLASTA*.
- ACLASTA*'s infusion should take a minimum of 15 minutes.
Novartis has also sent a letter [novartis.ca] to healthcare professionals to inform them of this new safety information. A copy of that letter is available on the Health Canada website.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious overdose symptoms or other serious or unexpected adverse reactions in patients receiving ACLASTA* should be reported to Novartis Pharmaceuticals Canada Inc. or Health Canada at the following addresses:
385 Bouchard blvd,
Dorval, Quebec, H9S 1A9
Telephone: 1-800-363-8883 (Medical Information)
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Reporting Form and:
- Fax toll-free to 1-866-678-6789, or
- Mail to: Canada Vigilance Program
- Health Canada
Postal Locator 0701E
Ottawa, Ontario K1A 0K9
- Health Canada
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of ACLASTA* (zoledronic acid), please contact Novartis Pharmaceuticals Canada Inc., Medical Information Department at 1-800-363-8883.
Sincerely,
original signed by
Jean-Marie Leclerc, M.D. FRCP(C)
Chief Scientific Officer and Senior Vice-President Clinical and Regulatory Affairs
*ACLASTA is a registered trademark
References:
ACLASTA* is approved for the treatment and prevention of osteoporosis in postmenopausal women, to increase bone mass in men with osteoporosis, for treatment and prevention of glucocorticoid-induced osteoporosis and for the treatment of Paget's disease of bone.
